Jazz Pharmaceuticals PLC Form 4 insider transactions

Jazz Pharmaceuticals Director Bruce C. Cozadd sold 6,000 ordinary shares on July 1, 2026, under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals executive Samantha Pearce reported a disposition of ordinary shares, primarily to cover tax obligations.

Renee D. Gala, President & CEO of Jazz Pharmaceuticals, reported a transaction involving the sale of ordinary shares.

Jazz Pharmaceuticals plc reports a transaction where EVP Robert Iannone sold shares to cover tax obligations.

Jazz Pharmaceuticals plc reports a transaction where EVP & Chief Legal Officer Neena M. Patil disposed of shares to cover tax obligations.

Jazz Pharmaceuticals plc executive Philip L. Johnson reported a transaction involving the withholding of shares to cover tax obligations and an acquisition of shares through an employee stock purchase plan.

Jazz Pharmaceuticals director Mark Douglas Smith executed a transaction under a pre-arranged 10b5-1 plan, selling shares at $230.55.

Neena M. Patil, EVP and Chief Legal Officer of Jazz Pharmaceuticals, sold 1,200 ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals CEO Renee Gala donated 600 ordinary shares to a donor-advised fund on June 3, 2026.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported a sale of 6,000 ordinary shares for $235.12 per share, executed under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals plc reports a Form 4 filing detailing a transaction by EVP & Chief Legal Officer Neena M. Patil involving the sale of ordinary shares.

Jazz Pharmaceuticals plc reports a transaction by Director Seamus Mulligan involving the acquisition of ordinary shares and the exercise of a stock option.

Director Rick E. Winningham exercised stock options and sold a portion of the resulting shares in Jazz Pharmaceuticals.

Director Heather Ann McSharry sold 2,000 ordinary shares of Jazz Pharmaceuticals plc at a price of $241 per share.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported a transaction involving the acquisition of 6,000 ordinary shares on May 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Director Bruce C. Cozadd reported the sale of ordinary shares valued at approximately $190 per share, executed under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 5,900 ordinary shares through a Rule 10b5-1 trading plan on March 3, 2026.

Jazz Pharmaceuticals director Norbert G. Riedel exercised stock options and subsequently sold an equal number of ordinary shares.

Jazz Pharmaceuticals plc's EVP & Chief Financial Officer, Philip L. Johnson, reported the acquisition of 11,857 restricted stock units and additional shares through an employee stock purchase plan.

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, was granted 9,782 restricted stock units, vesting over four years.

Jazz Pharmaceuticals' EVP, Global Head of R&D & CMO, Robert Iannone, was granted 14,822 restricted stock units.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported the acquisition of shares from RSU vesting and subsequent sales, including for tax obligations.

Jazz Pharmaceuticals plc's President & CEO, Renee D. Gala, was granted 44,465 restricted stock units, aligning executive incentives with long-term company performance.

Jazz Pharmaceuticals plc director Ted W. Love was granted 1,527 restricted stock units, vesting fully on July 24, 2026.

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M Patil, exercised stock options and sold a significant number of ordinary shares on February 26, 2026.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 5,343 ordinary shares to cover tax obligations following the vesting of restricted stock units.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, vested 10,116 performance-based ordinary shares on January 16, 2026.

Jazz Pharmaceuticals' SVP, Chief Accounting Officer, Patricia Carr, acquired 2,370 ordinary shares following the vesting of performance-based awards.

Jazz Pharmaceuticals plc's EVP & Chief Legal Officer, Neena M Patil, reported the acquisition of 8,852 ordinary shares from performance awards and the disposition of 3,275 shares for tax obligations.

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, reported the acquisition of shares from performance awards and an employee stock purchase plan, alongside a tax-related disposition.